Xbrane Biopharma AB
The answer first
Does Xbrane Biopharma beat the market?
No, Xbrane Biopharma has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 73% of Nordic stocks
- Quality50
- Value53
- Trend84
No. 32 of 195 in healthcare
Max for seven days
Follow Xbrane Biopharma with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 19 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Xbrane Biopharma
Your first answer is free, no account needed.
Do you own Xbrane Biopharma, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Xbrane Biopharma and a few more. Free, no card.
Super Stock+44.6%In short
- Xbrane Biopharma has risen 15.5% over the past year, including dividends.
- Overall, Xbrane Biopharma ranks better than 73% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 99.6%. The price is 99.5% below its peak now.
What do analysts think of Xbrane Biopharma?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 73% of Nordic stocks.
No. 32 of 195 in healthcare
Medium An average company: the accounts are neither especially strong nor weak.
No. 130 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.24
- Asset turnoverSales divided by everything the company owns0.21
- Return on equityProfit divided by equity−11.7%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Medium Fair price: about the same as a typical Nordic stock.
No. 48 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity0.4
- P/SPrice divided by sales1.8
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
High Tailwind in the share price: it has risen more than most over the last year.
No. 36 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months+21.1%
- 6 months−0.9%
- 9 months+22.4%
- 12 months+15.5%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Xbrane Biopharma
2 funds we follow own Xbrane Biopharma. The share is how much of the fund the stock makes up.
- Sweden2
From the funds' latest known holdings.
About Xbrane Biopharma
Xbrane Biopharma AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 28 employees.
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. It offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults.


See the full analysis of Xbrane Biopharma.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card